U.S. Markets close in 20 mins
  • S&P 500

    4,698.35
    +11.60 (+0.25%)
     
  • Dow 30

    35,735.12
    +15.69 (+0.04%)
     
  • Nasdaq

    15,770.30
    +83.39 (+0.53%)
     
  • Russell 2000

    2,274.74
    +20.96 (+0.93%)
     
  • Crude Oil

    72.55
    +0.50 (+0.69%)
     
  • Gold

    1,787.70
    +3.00 (+0.17%)
     
  • Silver

    22.49
    -0.03 (-0.15%)
     
  • EUR/USD

    1.1356
    +0.0083 (+0.7381%)
     
  • 10-Yr Bond

    1.5090
    +0.0290 (+1.96%)
     
  • Vix

    20.17
    -1.72 (-7.86%)
     
  • GBP/USD

    1.3237
    -0.0005 (-0.0357%)
     
  • USD/JPY

    113.6380
    +0.0980 (+0.0863%)
     
  • BTC-USD

    50,703.44
    +314.17 (+0.62%)
     
  • CMC Crypto 200

    1,321.06
    +15.94 (+1.22%)
     
  • FTSE 100

    7,337.05
    -2.85 (-0.04%)
     
  • Nikkei 225

    28,860.62
    +405.02 (+1.42%)
     

Clearmind Medicine To Fund Second R&D Partnership With Hebrew University's Technology Transfer Company

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Toronto, Ontario--(Newsfile Corp. - September 27, 2021) - Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce it has entered an agreement to fund a second research and development project with Yissum Research Development Company ("Yissum"), the technology transfer company of The Hebrew University of Jerusalem.

The project is consistent with the Company's focus on developing novel therapies that improve mental health, particularly those relating to addiction, binge behavior and depression.

About Yissum Research Development Corporation

Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum's mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. Yissum has registered over 10,875+ patents globally; licensed over 1140+ technologies and has spun out more than 191 companies. Yissum's business partners span the globe and include companies such as Boston Scientific, Google, ICL, Intel, Johnson & Johnson, Merck, Microsoft, Novartis and many more. For further information please visit www.yissum.co.il.

About the Hebrew University of Jerusalem

The Hebrew University of Jerusalem is Israel's first university, formed in 1918 and opened in 1925. Today, there are over 23,000 students enrolled at the University, including undergraduates, master's degree students, and doctoral candidates. The university has four campuses: Mount Scopus, The Edmond J. Safra (Givat Ram) Campus, and Ein Kerem (in Jerusalem), and Rehovot. Hebrew University Alumni are invited to visit https://new.huji.ac.il.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company's intellectual portfolio currently consists of two patent families. The first, "Binge Behavior Regulators", has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, "Alcohol Beverage Substitute", has been approved for a European patent, with pending applications in the U.S., China and India. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol "CWYO."

For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (778) 400-5347
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company's business strategy. There is no certainty that any of these events will occur. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the "CSE") nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Not for distribution to U.S. newswire services or dissemination in the United States.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97709